VV extracorporeal life support for the Third Millennium: will we need anticoagulation?

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Journal of Thoracic Disease

• Publication date

  2018-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.21037/jtd.2017.11.89PMID 29732189PMCID PMC5911561
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Thromboprophylaxis in Extracorporeal Circuits: Current Pharmacological Strategies and Future Directions

  2017cited by this paper
• The history and Development of Extracorporeal Support

  2017cited by this paper
• Heparin induced thrombocytopenia with mechanical circulatory support devices: review of the literature and management considerations

  2017influential reference
• The immobilization of a direct thrombin inhibitor to a polyurethane as a nonthrombogenic surface coating for extracorporeal circulation.

  2016cited by this paper
• Nanostructured metal–organic frameworks and their bio-related applications

  2016cited by this paper
• A prospective randomized trial comparing the clinical effectiveness and biocompatibility of heparin-coated circuits and PMEA-coated circuits in pediatric cardiopulmonary bypass

  2016influential reference
• Water-Stable Metal-Organic Framework/Polymer Composites Compatible with Human Hepatocytes.

  2016cited by this paper
• Anticoagulation Management and Monitoring during Pediatric Extracorporeal Life Support: A Review of Current Issues

  2016cited by this paper
• Poly-2-methoxyethylacrylate-coated cardiopulmonary bypass circuit can reduce transfusion of platelet products compared to heparin-coated circuit during aortic arch surgery

  2016cited by this paper
• Do we need heparin coating for extracorporeal membrane oxygenation? New concepts and controversial positions about coating surfaces of extracorporeal circuits.

  2015cited by this paper
• Anticoagulation for Extracorporeal Life Support: Direct Thrombin Inhibitors and Heparin

  2015cited by this paper
• In situ Endothelialization: Bioengineering Considerations to Translation.

  2015cited by this paper
• Nitric oxide-releasing S-nitrosated derivatives of chitin and chitosan for biomedical applications.

  2014cited by this paper
• The Dosing and Monitoring of Argatroban for Heparin-Induced Thrombocytopenia during Extracorporeal Membrane Oxygenation: A Word of Caution

  2014influential reference
• Endothelialization of implanted cardiovascular biomaterial surfaces: the development from in vitro to in vivo.

  2014cited by this paper
• Variability in Anticoagulation Management of Patients on Extracorporeal Membrane Oxygenation: An International Survey*

  2013cited by this paper
• A new phosphorylcholine-coated polymethylpentene oxygenator for extracorporeal membrane oxygenation: a preliminary experience

  2013cited by this paper
• The Chemistry and Applications of Metal-Organic Frameworks

  2013cited by this paper
• Bivalirudin in Pediatric Patients Maintained on Extracorporeal Life Support

  2013cited by this paper
• Strategies and Techniques to Enhance the In Situ Endothelialization of Small-Diameter Biodegradable Polymeric Vascular Grafts

  2013cited by this paper
• Bivalirudin versus heparin as an anticoagulant during extracorporeal membrane oxygenation: a case-control study.

  2013cited by this paper
• Bivalirudin and post-cardiotomy ECMO: a word of caution

  2012cited by this paper
• Metal-organic frameworks in biomedicine.

  2012cited by this paper
• Polymer‐Based Nitric Oxide Therapies: Recent Insights for Biomedical Applications

  2012cited by this paper
• ECMO : extracorporeal cardiopulmonary support in critical care

  2012cited by this paper
• Is a fully heparin-bonded cardiopulmonary bypass circuit superior to a standard cardiopulmonary bypass circuit?

  2012cited by this paper
• Bivalirudin-based versus conventional heparin anticoagulation for postcardiotomy extracorporeal membrane oxygenation

  2011cited by this paper
• Heparinized cardiopulmonary bypass circuits and low systemic anticoagulation: an analysis of nearly 6000 patients undergoing coronary artery bypass grafting.

  2011cited by this paper
• The hemocompatibility of a nitric oxide generating polymer that catalyzes S-nitrosothiol decomposition in an extracorporeal circulation model.

  2011cited by this paper
• Protein interactions with surfaces: cellular responses, complement activation, and newer methods.

  2011cited by this paper
• Biomedical Applications of Metal Organic Frameworks

  2011cited by this paper
• Active or passive bio-coating: does it matters in extracorporeal circulation?

  2011cited by this paper
• The artificial endothelium

  2011cited by this paper
• Update on Antithrombotic Therapy: New Anticoagulants

  2010cited by this paper
• Modified surface coatings and their effect on drug adsorption within the extracorporeal life support circuit.

  2010cited by this paper
• The impact of different biocompatible coated cardiopulmonary bypass circuits on inflammatory response and oxidative stress

  2010cited by this paper
• BioMOFs: metal-organic frameworks for biological and medical applications.

  2010cited by this paper
• Extracorporeal membrane oxygenation bridging to lung transplant complicated by heparin-induced thrombocytopenia.

  2010influential reference
• Induction of EPC homing on biofunctionalized vascular grafts for rapid in vivo self-endothelialization--a review of current strategies.

  2010cited by this paper
• Evaluation of hemodynamic and regional tissue perfusion effects of minimized extracorporeal circulation (MECC).

  2010cited by this paper
• Nitric oxide-releasing vehicles for biomedical applications

  2010cited by this paper
• Clinical performance and biocompatibility of hyaluronan-based heparin-bonded extracorporeal circuits in different risk cohorts.

  2010cited by this paper
• Trends and emerging technologies in extracorporeal life support: results of the 2006 ECLS survey.

  2009cited by this paper
• Postsynthetic modifications of iron-carboxylate nanoscale metal-organic frameworks for imaging and drug delivery.

  2009cited by this paper
• The impact of different biocompatible coated cardiopulmonary bypass circuits on inflammatory response and oxidative stress

  2009cited by this paper
• Contact activation of blood-plasma coagulation.

  2009cited by this paper
• Bioline® heparin-coated ECMO with bivalirudin anticoagulation in a patient with acute heparin-induced thrombocytopenia: the immune reaction appeared to continue unabated

  2009cited by this paper
• A systematic review of biocompatible cardiopulmonary bypass circuits and clinical outcome.

  2009cited by this paper
• Effect of varying nitric oxide release to prevent platelet consumption and preserve platelet function in an in vivo model of extracorporeal circulation

  2007cited by this paper
• Recombinant activated factor VII effectively reverses the anticoagulant effects of heparin, enoxaparin, fondaparinux, argatroban, and bivalirudin ex vivo as measured using thromboelastography

  2007cited by this paper
• Heparin-bonded circuits versus nonheparin-bonded circuits: an evaluation of their effect on clinical outcomes.

  2007cited by this paper
• Argatroban in extracorporeal membrane oxygenation.

  2007influential reference
• Deep Hypothermic Circulatory Arrest and Bivalirudin Use in a Patient With Heparin‐Induced Thrombocytopenia and Antiphospholipid Syndrome

  2007cited by this paper
• Recent developments in nitric oxide donor drugs

  2007cited by this paper
• Phosphorylcholine coating may limit thrombin formation during high-risk cardiac surgery: a randomized controlled trial.

  2006cited by this paper
• Nitric oxide releasing polyurethanes with covalently linked diazeniumdiolated secondary amines.

  2006cited by this paper
• Heparin-induced thrombocytopenia in a pediatric patient receiving extracorporeal membrane oxygenation managed with argatroban‡

  2006influential reference
• New anticoagulants.

  2005cited by this paper
• Biomaterial-associated thrombosis: roles of coagulation factors, complement, platelets and leukocytes.

  2004cited by this paper
• Reduced Systemic Heparin Dose with Phosphorylcholine Coated Closed Circuit in Coronary Operations

  2004cited by this paper
• Phosphorylcholine or heparin coating for pediatric extracorporeal circulation causes similar biologic effects in neonates and infants.

  2004cited by this paper
• Argatroban usage for anticoagulation for ECMO on a post-cardiac patient with heparin-induced thrombocytopenia.

  2004influential reference
• Argatroban as an alternative to heparin in extracorporeal membrane oxygenation circuits

  2004influential reference
• S-nitrosothiols as nitric oxide-donors: chemistry, biology and possible future therapeutic applications.

  2004cited by this paper
• A prospective, double-blind study on the efficacy of the bioline surface-heparinized extracorporeal perfusion circuit.

  2003cited by this paper
• Nitric oxide and S-nitrosothiols in human blood.

  2003cited by this paper
• Closed, phosphorylcholine-coated circuit and reduction of systemic heparinization for cardiopulmonary bypass: the intraoperative ECMO concept.

  2002cited by this paper
• Argatroban in adult extracorporeal membrane oxygenation.

  2002influential reference
• Bivalirudin: a direct thrombin inhibitor.

  2002cited by this paper
• Biocompatibility of Trillium Biopassive Surface-coated oxygenator versus uncoated oxygenator during cardiopulmonary bypass.

  2001cited by this paper
• Prevalence and persistence of heparin/platelet factor 4 antibodies in patients with heparin coated and noncoated ventricular assist devices.

  2000cited by this paper
• Phosphorylcholine coating of extracorporeal circuits provides natural protection against blood activation by the material surface.

  2000cited by this paper
• A prospective randomized trial of Duraflo II heparin-coated circuits in cardiac reoperations.

  1999cited by this paper
• Estimation of nitric oxide production and reactionrates in tissue by use of a mathematical model.

  1998cited by this paper
• Duraflo II coating of cardiopulmonary bypass circuits reduces complement activation, but does not affect the release of granulocyte enzymes : a European multicentre study.

  1997cited by this paper
• Extracorporeal circulation, hemocompatibility, and biomaterials.

  1996cited by this paper
• Surface-bound heparin fails to reduce thrombin formation during clinical cardiopulmonary bypass.

  1996cited by this paper
• The effects of Carmeda Bioactive Surface on human blood components during simulated extracorporeal circulation.

  1996cited by this paper
• Reduced complement activation and improved postoperative performance after cardiopulmonary bypass with heparin-coated circuits.

  1995cited by this paper
• Evaluation of Phospholipidic Surface Coatings ex-vivo

  1994cited by this paper
• Polymeric biomaterials: influence of phosphorylcholine polar groups on protein adsorption and complement activation

  1994cited by this paper
• Pathology of atrioventricular valve dysplasia.

  1993cited by this paper
• Nitric oxide circulates in mammalian plasma primarily as an S-nitroso adduct of serum albumin.

  1992cited by this paper
• Endothelialization of the luminal sac in artificial cardiac prostheses: a challenge for both biologists and engineers.

  1991cited by this paper
• Effect of heparin and heparin fractions on platelet aggregation.

  1980cited by this paper
• Heparin Bonding on Colloidal Graphite Surfaces

  1963cited by this paper
• The Nomenclature of Blood Clotting Factors

  1962cited by this paper
• Nomenclature of Blood Clotting Factors

  1959cited by this paper
• The Discovery of Heparin

  1959cited by this paper

• Preclinical Testing of a Novel Extracorporeal Membrane Oxygenation System in an Acute Cardiogenic Shock Animal Model

  2025cites this paper
• Evolution of extracorporeal membrane oxygenation: historical milestones and advanced developments

  2025cites this paper
• Miniaturization of Artificial Lungs toward Portability

  2020cites this paper
• Anticoagulation strategies in extracorporeal circulatory devices in adult populations

  2020cites this paper
• The effect of hyperoxia on inflammation and platelet responses in an ex vivo extracorporeal membrane oxygenation circuit.

  2020cites this paper
• Post-operative of bleeding, haemolysis and coagulation in mechanical circulatory support patients

  2020cites this paper
• Evaluation of Novel Hemocompatible Surface Coatings for Extracorporeal Life Support: A Biocompatible Alternative to Systemic Anticoagulation

  2019cites this paper
• Pediatric ECMO Research: The Case for Collaboration

  2018cites this paper
• Novel Surfaces in Extracorporeal Membrane Oxygenation Circuits

  2018cites this paper